Exhibit 99.2

                         PharmaFrontiers Completes $23
      Million Financing to Advance Therapeutics; Plans Reverse Stock Split

     THE WOODLANDS, Texas--(BUSINESS WIRE)--April 17, 2006--
PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the
development and commercialization of cell therapies, has raised
approximately $23 million in a private placement to institutional and
other accredited investors of approximately 23 million units at $1.00
per unit, comprised of two shares of newly issued common stock and a
five-year redeemable warrant to purchase one share of common stock at
an exercise price of $0.65 per share. MDB Capital Group LLC acted as
the exclusive placement agent.
    The proceeds will be used primarily to fund PharmaFrontiers' Phase
IIb trial with Tovaxin(TM) for the treatment of multiple sclerosis.
The Company expects to begin the trial in the second quarter of 2006.
The funds will also be used to complete pre-clinical development and
initiate human clinical trials of the Company's rheumatoid arthritis
and Type 1 diabetes therapies.
    In connection with the private placement, PharmaFrontiers has
agreed to file a registration statement on Form SB-2 by May 13, 2006
to register the resale of the shares of common stock and the shares
underlying the warrants.
    In addition, the Company announced that its board of directors has
approved, and will recommend to the Company's shareholders for their
approval, a one-for-ten reverse stock split. PharmaFrontiers believes
this reverse stock split will enable the Company to apply for a
listing on Nasdaq.
    David B. McWilliams, chief executive officer of PharmaFrontiers,
commented, "This additional capital is a tremendous catalyst for the
Company and will provide us with the financial resources to implement
our clinical program, for both our T-cell and stem cell technologies
and to fulfill their potential as life-saving therapies. We believe
that the strengthening of our capital structure in connection with the
reverse stock split will provide the backbone for a strong
organization with prospects for a Nasdaq listing."

    About PharmaFrontiers Corp.

    PharmaFrontiers' strategy is to develop and commercialize cell
therapies to treat several major disease areas such as multiple
sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions.
PharmaFrontiers has exclusive license from Baylor College of Medicine
for individualized cell therapies that will be starting an FDA Phase
IIb clinical trial to evaluate effectiveness in treating MS. The
company also holds the exclusive worldwide license for an autologous T
cell vaccine for rheumatoid arthritis from the Shanghai Institutes for
Biological Sciences (SIBS), Chinese Academy of Sciences of the
People's Republic of China. The company also holds the exclusive
worldwide license from the University of Chicago, through its prime
contractor relationship with Argonne National Laboratory, for patents
relating to the use of adult pluripotent stem cells derived from
patients' own circulating blood.

    About MDB Capital Group LLC

    MDB Capital Group is a research driven investment bank providing
financial services to emerging growth companies, as well as
institutional asset management firms, mutual funds, hedge funds and
high net worth individuals.

    Founded in 1997, MDB provides the following professional services:

    --  Equity Research

    --  Equity Sales and Trading

    --  Investment Banking

    --  Fixed Income Sales and Trading

    MDB is an NASD licensed broker-dealer and a member of the
Securities Investor Protection Corporation ("SIPC"). MDB is based in
Santa Monica, CA with an office in New York City.

    Safe Harbor Statement

    This press release contains "forward-looking statements,"
including statements about PharmaFrontiers' growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that are
not historical facts or information. These forward-looking statements
are based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors, specifically
including those relating to PharmaFrontiers' ability to obtain
additional funding, develop its stem cell technologies, achieve its
operational objectives, and obtain patent protection for its
discoveries, that may cause PharmaFrontiers' actual results to be
materially different from any future results expressed or implied by
such forward-looking statements. PharmaFrontiers undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.

    CONTACT: PharmaFrontiers Corp.
             Lynne Hohlfeld, 281-719-3421
             lhohlfeld@pharmafrontierscorp.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or
             Bruce Voss, 310-691-7100
             bvoss@lhai.com